Rden of Hepatitic C Connected Illnesses within the United states of america. J Viral Hepat 2012, 19(three):15360. eight. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The growing burden of mortality from viral hepatitis within the United states involving 1999 and 2007. Ann Intern Med 2012, 156(four):27178. 9. Razavi H, El Khoury A, Elbasha E, Estes C, Pasini K, Poynard T, Kumar R: Chronic Hepatitis C Virus (Hcv) Disease Burden and Cost in the Usa. Hepatol 2012: . doi:10.1002/hep.26218 [Epub ahead of print]. 10. Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting future complications of chronic hepatitis C within the United states. Liver Transpl 2003, 9(4):33138. 11. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for any unified system of nomenclature of hepatitis C virus genotypes. Hepatol 2005, 42:96273. 12. Wilkins T, Malcolm JK, Raina D, Schade RR: Hepatitis C: diagnosis and therapy. Am Fam Physician 2010, 81(11):1351357. 13. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatol 2009, 49(4):1335374. 14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa.b plus ribavirin compared with interferon alfab plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:95865. 15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon les FL Jr, H ssinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfaa plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:97582. 16. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group: Peginterferon alfab and ribavirin for the therapy of chronic hepatitis C in blacks and non ispanic whites. N Engl J Med 2004, 350:2265271. Erratum, N Engl J Med 2004;351:1268. 17. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection.Dihydroartemisinin N Engl J Med 2011, 364(13):1195206.Dihydromethysticin 18.PMID:23983589 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, HCV RESPOND-2 Investigators: Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207217. 19. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Group: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2407416.20. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, M lhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, Comprehend Study Group: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417428. 21. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB:.
